Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy (Q38465537)

3 September 2017

Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy (English)

1 reference

3 September 2017

4

Nam-Sun Paik

1 reference

3 September 2017

3

Byung-In Moon

1 reference

3 September 2017

Anbok Lee

1

1 reference

3 September 2017

Woosung Lim

series ordinal

2

1 reference

3 September 2017

Suck-Hwan Koh

series ordinal

5

1 reference

3 September 2017

Jeong-Yoon Song

series ordinal

6

1 reference

3 September 2017

language of work or name

1 reference

27 December 2011

1 reference

3 September 2017

Journal of breast cancer

1 reference

3 September 2017

14

1 reference

3 September 2017

4

1 reference

3 September 2017

283-288

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

3 September 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Predicting anthracycline benefit: have we made any progress?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Clinicopathological features and treatment strategy for triple-negative breast cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268924

Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

31 August 2018

1 reference

12 December 2020

Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results

1 reference

12 December 2020

Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing

1 reference

12 December 2020

Paclitaxel and docetaxel in the treatment of breast cancer

1 reference

12 December 2020

10.4048/JBC.2011.14.4.283

Identifiers

DOI

1 reference

3 September 2017

1 reference

3 September 2017

PubMed publication ID

22323914

1 reference